Varying concentrations of blood components in platelet-rich plasma preparations may contribute to the variable results seen in recently published clinical studies. The purposes of this investigation were (1) to quantify the level of platelets, growth factors, red blood cells, and white blood cells in so-called one-step (clinically used commercial devices) and two-step separation systems and (2) to determine the influence of three separate blood draws on the resulting components of platelet-rich plasma.
PLATELET-RICH PLASMA DIFFERS ACCORDING TO PREPARATION METHOD AND HUMAN VARIABILITY ricH plasma is a generic term referring to any sample of autologous plasma with platelet concentrations above baseline blood values2. Defining platelet-rich plasma preparations according to platelet count can be difficult, as consensus on adequate concentration is lacking. Platelet concentrations of 200 X 103 platelets/u,L up to 1000 X 103 platelets/|xL are considered therapeutic for tissuehealing, whereas much higher counts appear to be biologically unfavorable1'4"6. Describing platelet-rich plasma according to the method of production may be more appropriate as either one or two-step centrifugation processes are used to fraction whole blood and concentrate the platelets1'3'7.
Currently, there are several commercial devices available for the preparation of platelet-rich plasma. While their common purpose is to fraction whole blood into its composite parts to allow isolation of plasma with elevated levels of platelets, each device functions differently. Specifically, these devices and their protocols differ in their method of isolation (one or twostep centrifugation), type and operation of the collecting tube, speed of the centrifuge, and other processes of production, which result in plasma preparations with varying volumes, platelet numbers, quantities of growth factors, and concentrations of residual white and red blood cells1'3'7'8.
Variability in the cellular composition of platelet-rich plasma preparations can create methodological challenges for investigators1'3'7. Results obtained from both in vitro and in vivo studies utilizing platelet-rich plasma can be difficult to interpret if cell type and quantity of the plasma preparations are inconsistent. Despite its importance, research to quantify differences in separation methods is limited. Recently, Castillo et al. compared cell concentrations in platejet-rich plasma preparations from three different single-step separation methods (MTF Cascade, Arteriocyte Magellan, and Biomet GPS III)9. While concentrations of platelets, red blood cells, fibrinogen levels, and active TGF-J31 remained consistent, substantial differences in the amount of VEGF-A and PDGFs as well as the amount and concentration of white blood cells were observed9. Considering the concentration-dependent function of white blood cells to be either beneficial or harmful in platelet-rich plasma treatments, it is critical to define the differences in the cellular characteristics of platelet preparations10"12.
To elucidate differences between methods of procurement of platelet-rich plasma, laboratory investigation conducted in a clinically applicable manner is needed. Historically, basic-science investigation has utilized automatic call separation to produce platelet-rich plasma1. While valid, this method does not reflect a clinical environment in which centrifuge devices are used and platelet-rich plasma treatment is sometimes administered in repeated doses over a given period of time. These conditions raise questions over the consistency of platelet preparations with regard to methods of separation and within-individual consistency of preparations with repeated blood draws1.
Our hypotheses were that (1) despite variability in specific methods, so-called one-step separation methods will result in comparable preparations of platelet-rich plasma with regard to platelet, growth factor, and red and white blood-cell concentrations, and (2) inconsistent blood cell counts and concentrations will be seen with each system following repeated blood draws. Two major study goals developed for these hypotheses were (1) to quantify the level of platelets, growth factors, red blood cells, and white blood cells in onestep (clinically used commercial devices) and two-step separation systems (literature-based platelet-rich plasma method) and (2) to determine the influence of three separate blood draws in terms of within-subject differences on the resulting components of platelet-rich plasma.
Materials and Methods Subjects
B lood samples were obtained from eight healthy subjects (two female and six male subjects with a mean age [and standard deviation] of 31.6 ± 10.9 years) as part of an investigative study examining various properties of platelet-rich plasma; Institutional review board approval was obtained. Inclusion criteria included healthy subjects between the ages of eighteen and sixty-five years without known blood dyscrasia. Exclusion. criteria included a medical history of bloodderived illness or any medication known to affect platelet or bone 'marrow function or concentration for a minimum of two weeks prior to testing.
Platelet-Rich Plasma Preparation
Approximately 125 ml of peripheral blood was drawn from each subject at three different time points (zero, fourteen, and thirty days) to allow sufficient platelet recovery. A 60-mL syringe prefilled with 5 mL of acid citrate dextrose (ACD-A) was used for the standardized blood draw. ACD-A binds calcium and prevents blood dotting with no known interference to platelet function. Blood was then transferred directly to each of the three different separation systems. As separation methods, a single-spin method that would be expected to result in platelet-rich plasma (PPO?) with a lower platelet and white blood-cell number (PRPLP),-an alternative system expected to result in a high amount of platelets and high number of white blood cells (PPvPHp), and a double-spin method (PRPDS) were chosen to represent an overall survey of the techniques clinically available, The Arthrex AGP Double Syringe (Arthrex, Naples, Florida) was used for production of autologous conditioned plasma. Ten milliliters of blood was filled into the double syringe to produce 3 mL of PRPLP. Syringes were centrifuged at 1500 rpm for five minutes. This separated the erythrocytes from the remaining plasma components. The top portion of plasma was drawn, up with use of the inner syringe without disruption of the erythrocyte layer.
The GPS ILT Platelet Concentrate System (Biomet, Warsaw, Indiana) was used to produce approximately 3 mL of PRPHp out of 27 mL of blood. The tubes were centrifuged for-fifteen minutes at 3200 rpm according to the manufacturer's protocol With the specific construction of the tubes, it was possible to draw the portion of platelet-rich plasma into a 3-mL syringe according to the manufacturer's instructions.
.PRPns A literature-based double-spin method was utilized to fractionate whole blood13. After a first centrifugation of 1500 rpm for five minutes, the top layer of plasma was separated and centrifuged a second time (twenty minutes at 6300 rpm). Finally, half of the superficial plasma layer was removed, and the platelet pellet was suspended in the remaining half of the plasma volume.
Platelet Concentration and Number of Blood Cells
A 1-mL sample of each platelet-rich plasma preparation and each native blood specimen were analyzed by the clinical core laboratory at the. University of Connecticut Health Center. The platelet concentration, number of red blood cells, and white blood-cell differentiation was determined by blood .cell count (Gen-S System 2 Hematology Analyzer, Coulter, Miami,-Honda) . Linearity is 10 -1000 X 103/|jX for platelet count, 0.3 -7.0 X 106/u,L for red blood-cell count, and 0.1 -100 x 103/(iL for white blood-cell count, respectively (data provided by the University of Connecticut Health Center blood laboratory).
Growth Factor Concentration
Enzyme-linked immunosorbent assay (ELISA) in duplicate aliquots with the Quantikine Human Immunoassay kits (R&D Systems, Minneapolis, Minnesota) were used to quantify the growth factor concentration of each platelet-rich plasma preparation and native blood sample. Samples for each were immediately frozen (-20°) to preserve growth factor integrity, stored for less than twenty-eight days, and thawed on ice (one freeze-thaw cycle) before the ELISA assays were performed. Due to the high costs of the multiple ELISA assays, only quantification for all products of all subjects at the time point of the first blood draw was feasible. All assays had in common the employment of the quantitative sandwich enzyme immunoassay technique.
The growth factors EGF, FGF-2, HGF, IGF-1, PDGF-AB, TGF-|31, and VEGF-A were chosen for analysis because of their specific roles in tissue-healing '*The values area given as the mean platelet concentration (and standard deviation) of three repetitive blood draws (zero, fourteen, and thirty days) for each subject and overall (n = 8). Overall intrasubject variability was calculated with Cronbach a for standardized items for each product. PRPLp = platelet-rich plasma prepared with single-spin method resultingin lowernumberof white blood cellsand platelets, PRPHp=alternative method resultingin a high amount of white blood cells and platelets, and PRPDS = double-spin method.
and regeneration1'7. Human EGF was measured with a 3.5 to 4,5-hour solid phase ELISA containing Escherichia coK-derived recombinant human EGF and antibodies raised against the recombinant factor. The FGF basic (FGF-2) kit contained recombinant human FGF-2 and antibodies raised against the recombinant factor (4.5-hour solid phase). The 4.25 to 4.5-hour HGF ELISA contains S/21-expressed recombinant human pro-HGF and antibodies raised The concentration of platelets after rep etitive blood draws according to subject and group, including PRPu ( Fig. 3-A) , PRPHP ( Fig. 3-B) , and PRPDS ( Fig. 3-C) . 
Statistical Analysis
Data were analyzed with SPSS software (version 15.0; SPSS, Chicago, Illinois). The Kolmogorov-Smirnov and Shapiro-Wilk tests were performed for each variable to identify non-normal distributions. Since none of the variables showed normative distribution (p < 0.05), the nonparametric Kruskal-Wallis test was used to compare group means. Comparisons with a significant difference in means were followed by post hoc tests (Tamhane T2). A p value of <0.05 was used to determine significance. For comparison of the variability of repetitive blood draws, means and standard deviations were determined for each subject and overall. Additionally, Cronbach a was calculated as a measure of reliability with the intraclass correlation measurement for two-way random average measurements (ex > 0.7 was regarded as reliable). This was used as a measure of the internal consistency and/or reliability of a repetitive measure-' ment in multiple subjects.
Source of Funding
The University of Connecticut Health Center-New England Musculoskeletal Institute has received direct funding 'and material support for this study by Arthrex (Naples, Florida). The company had no influence on study design, data collection, or interpretation of the results.
Results

Platelet Concentration
W ith regard to the total number of platelets, all separation systems produced a significantly increased platelet number compared with native blood (142.7 ± 44.40 X 103/(xL). The PRPHp (873.8 ± 207.82 X lO3/^!) also showed a significantly higher number of platelets compared with PRPLp (378.3 + 58.64 X 103/(JiL) or PRPDS (447.7 + 183.7 X 103/jxL) (p < 0.05). No significant difference in platelet number was seen when PRPLi> was compared with PRPDS (p = 0.52) (Hg. 1).
•
Red Blood-Cell Concentration
Overall, the highest level of red blood cells was in native blood 142.9 ± 12.5 *EGF = epidermal growth factor, FGF-2 = fibroblast growth factor, HGF = hepatocyte growth factor, IGF = transforming growth factor-beta, and VEGF = vascular endothelial growth factor. tThe values are given as the PRPLP = platelet-rich plasma prepared with single-spin method resulting in lower number of white blood cells method resulting in a high amount of white blood cells and platelets, and PRPDS = double-spin method. fewer white blood cells (1.7 ± 1.8 X 103/pJl) than native blood (5.6 ± 1.7xl03/u,L) (Fig. 2) .
White Blood-Cell Distribution
The distribution of the white blood cells according to separation methods is shown in Table I . All cell types showed significant differences compared with each other (p < 0.05), except for PRPLP and PBJ?Ds> which showed no significant difference between any cell types. No significant differences were observed when numbers of eosinophils isolated from the PRPHp were compared with whole blood. Table II and Figures 3-A, 3 -B, and 3-C show the intrasubject and intersubject variability of platelet concentrations according to different blood draws.
Influence of Draw Repetition on Platelet Count
Growth Factors
Results for each growth factor are shown in Table III . The singlespin method (PPJ?LP) had a significantly higher concentration of the factors HGF, IGF-1 and PDGF-AJB in comparison with the double-spin method Q?RPDS), whereas'the PRPnp separation produced significantly more growth factors compared with the other separations, with the exception of YEGP-A (p < 0.05). The PRPu separation method released significantly more HGF, IGF-1, and PDGF-AB compared with the PRPDS separation (p < 0.05).
Discussion
T his study was designed to explore differences between methods of procurement and administration for plateletrich plasma. We observed.differing amounts of platelets, white blood cells, and growth factors with each method of separation as well as wide intrasubject variation in cell type and count with repetitive blood draws. However, as anticipated, all separation techniques resulted in a significant increase in platelet concentration compared with native blood1'2. Platelet concentrations in the PRPHp procedure were significantly higher than platelet concentrations in the single-step PRPLP and the two-step PRPD-S procedures; however, significant differences between PRPtp and ' PRPDS were not observed. While these data assist in determining the extent to which devices and repetitive blood draws influence the type and number of cells in platelet-rich plasma preparation, it does not provide proof of clinical efficacy. In this regard, the results observed in the present study between methods of procurement and repetitive blood draws are discussed with respect to previously published laboratory research on plasma preparations.
Previous investigators have defined platelet-rich plasma according to platelet concentration. Marx required plasma preparations to have a platelet concentration of 1000 X l_03/fj,L tojfa£_c&asjdeted-thefapcutic pla-tekfaich plasma4. In the present study, the PRPHp resulted in the highest amounts of platelets (873.8 ± 207.82 X 103/u,L), which approximately meets this criterion. Other investigators have reported lower platelet concentrations for therapeutic platelet-rich plasma. On the basis of the current use of centrifuges and plasma isolation procedures and the undetermined and unclear effect of platelets on targeted tissue, Mazzucco et al., in 2009 , defined platelet numbers of >200 x 1Q3/]1L as suttKienffoEi-tEegaficutic effect6. ThTs~TlefiiritioTr seems^reasonable, as platelet concentrations of approximately 2.5 times greater than native blood (142.7 ± 57.9 X 103/u,L) hayejrjgsitive effects on ostegblasts and fibroblasts in vitro. Additionally, adverse events have been observed at higher dosages (>3.5 times platelet concentration of native blood)15. While the other evaluated methods, PRPLp (378.3 ± 58.64 X 103/u,L) and PRPDS (447:7 ± 183.7 X 103/|_iL), resulted in significantly lower platelet numbers than the PRPHP, all methods exceeded concentrations of >300 X 103/u,L, thereby satisfying this criterion of >200 x 103/u,L.
Investigators have reported differences between one and, two-step procedures16. In the present study, comparison of the two-step procedure (PRPDS) did not result jn significantly higher levels of platelet separation than the one-step procedures (PRPHp and PRPLp). These results support the effectiveness of a one-step procedure to produce comparable amounts of platelets for therapeutic application. These data may be useful to clinicians as the .2 ± 292.6 X 103/|JuL)9. We utilized three repeated measurements to establish mean values, which resulted in concentrations closely matching the manufacturer's information (platelet numbers that were nine times that of native blood) and other published data3. Interestingly, both studies demonstrated high standard deviations, indicating significant variability in the data. While each used subjects with comparable ages, the difference in results may be due to variability within individuals in each study as well as to the number of subjects.
The quantity of white blood cells in plasma preparations is of particular interest. Amounts of white blood cells and their effect in platelet-rich plasma application have been widely discussed. Some investigators have recommended avoiding tissue exposure to white blood cells as an inflammatory reaction may occur3'17. Other investigators have reported_a_benefi-cial effect of white blobtr-eells-ttrferrrisTrfirlcre andHimmunologicaj-resistance18'19. AdditionalLy^-wfaite-bk) o d cellshave beerj^j^noLled-4o--66ffeSre~with increased growth factor release20. Our results demonstrate significant differences in whterblood cells by the production method, which is consistent with other investigators who have reported similar differences between production methods9.
The differentiation of white blood-cell types may permit estimation of their respective effects. We evaluated the type of white blood cells present in each plasma preparation. As expected, the overall number of each type of white blood cells was significantly higher with the PRPnp separation method. Quantities of lymphocytes were more than quadrupled and neutrophils were more than doubled compared with native blood with this technique. While these cell types have been reported to produce negative effects on tissue-healing because of their capacity to promote inflammatory effects11 '19 , there is no clinical evidence to support their effect on cells. Rather, these data are intended to provide clinicians with data to assist in choosing a separation method to match the intended_ase_of platelet-rich plasma. " GrowthTactor analysis~was also performed in the present study for all platelet-rich plasma preparations in all subjects at the time point of the first blood draw. The single-spin method (PRPLP) had a significantly higher concentration of the factors HGF, IGF-1, and PDGF-AB in comparison with the double-spin method (PRPos); whereas the PRPHp separation produced significantly more growth factors compared with the other separations, with the exception ofVEGF-A. This increase maybe due in part to higher amounts of white blood cells and/or platelets, which correlate with variable levels of growth factors in different methods of platelet-rich plasma preparations12'21. Considering the results of the variability in platelet concentrations observed for repetitive blood draws, high variability in growth factor content might also be present for platelet-rich plasma preparations separated from repetitive blood draws. Additionally, quantifying growth factors can be performed through the activation of platelets with the application of calcium chloride or thrombin to stimulate complete release, which has been shown to substantially increase the locally available growth factor content22. In the present study, platelet activation was not performed to evaluate the physiologic growth factor levels.
Comparison of our results with-the data of Castillo et al. revealed that different levels of growth factors were observed for the same separation systems9. Considering their results were higher than other reported data, contributing factors, including mechanical forces induced during the handling process, were discussed as potential causes of increased growth factors released9. According to the manufacturer's data (Quantikine ELISA kits; R&D Systems), incomplete removal of platelets and blood cells may cause variable results for assays of factors contained in platelets, although data within studies are comparable. Because of red blood-cell concentration, ELISA data should only be compared within studies, and. comparison with other studies can only be performed with limitations.
We observed significant variation in platelets and white blood cells with repetitive blood draws from the same individual at different times for all methods of platelet-rich plasma separation. In an effort to quantify the degree to which blood draws produced consistent amounts of blood cells, Cronbach a was calculated for all individuals. The cell counts in the native blood of all included subjects were consistent between the three . blood draws (zero, fourteen, and thirty days). However, the platelet concentration of all three methods showed a high variability Avithin the subjects for the three time points. Considering platelet-rich plasma application methods tend toward a repetitive treatment, the lack of consistency at the level of the individual is important, as reliable platelet-rich plasma dosages may be needed to produce consistent results1. There are several limitations of this study. The sample size (eight 'subjects), although consistent with other plateletrich plasma-related reports, may have impacted the study results1'3'7. Variability due to different subjects and possible alterations in production methods impact the ability to compare our results with previously published data! We attempted to evaluate representative separation methods; however, since there are multiple methods commercially available, a study comparing all of the different available platelet-rich plasma kits would be financially prohibitive. As a result, we examined the higher (PRPHP) and lower (PRPLP) spectrum of routine platelet-rich plasma separation methods.
